P&G Banks $500 Million of Cost Relief and Guides None of It: The Beat Funds a Share War It Is Currently Losing
PG financial model
Income Statement · Dollars in millions, except per share
| Income Statement | ||||||
|---|---|---|---|---|---|---|
| Actual | Estimate | |||||
| FY24 | FY25 | FY26 | FY27E | FY28E | FY29E | |
| Total Net Sales | $84,039.0 | $84,284.0 | $87,032.0 | $88,723.9 | $90,655.2 | $92,633.4 |
| Less: Cost of Products Sold | ($40,848.0) | ($41,164.0) | ($43,362.0) | ($44,525.0) | ($45,222.3) | ($46,038.8) |
| Gross Profit | $43,191.0 | $43,120.0 | $43,670.0 | $44,198.9 | $45,433.0 | $46,594.6 |
| Less: Selling, General and Administrative Expense | (23,305.0) | (22,669.0) | (23,922.0) | (23,695.9) | (24,121.0) | (24,733.1) |
| Less: Indefinite-Lived Intangible Asset Impairment | (1,341.0) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Operating Expenses | ($24,646.0) | ($22,669.0) | ($23,922.0) | ($23,695.9) | ($24,121.0) | ($24,733.1) |
| Operating Income | $18,545.0 | $20,451.0 | $19,748.0 | $20,503.0 | $21,312.0 | $21,861.5 |
| Less: Interest Expense | (925.0) | (907.0) | (877.0) | (1,050.1) | (1,050.1) | (1,051.5) |
| Interest Income | 473.0 | 469.0 | 430.0 | 398.4 | 458.6 | 520.4 |
| Other Non-Operating Income/(Expense), Net | 668.0 | 154.0 | 1,076.0 | 876.4 | 895.5 | 917.1 |
| Rounding Residual | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Earnings Before Income Taxes | $18,761.0 | $20,167.0 | $20,377.0 | $20,727.7 | $21,616.0 | $22,247.5 |
| Less: Income Taxes | ($3,787.0) | ($4,102.0) | ($4,233.0) | ($4,311.4) | ($4,496.1) | ($4,627.5) |
| Net Earnings | $14,974.0 | $16,065.0 | $16,144.0 | $16,416.3 | $17,119.9 | $17,620.0 |
| Less: Net Earnings Attributable to Noncontrolling Interests | (95.0) | (91.0) | (98.0) | (98.5) | (102.7) | (105.7) |
| Net Earnings Attributable to Procter & Gamble | $14,879.0 | $15,974.0 | $16,046.0 | $16,317.8 | $17,017.2 | $17,514.3 |
| Less: Preferred Dividends | (284.0) | (291.0) | (292.0) | (281.1) | (273.3) | (268.3) |
| Net Earnings Available to Common Shareholders | $14,595.0 | $15,683.0 | $15,754.0 | $16,036.7 | $16,743.9 | $17,246.0 |
| Ratios & Assumptions | ||||||
| YoY Total Net Sales Growth | 2.5% | 0.3% | 3.3% | 1.9% | 2.2% | 2.2% |
| Gross Margin | 51.4% | 51.2% | 50.2% | 49.8% | 50.1% | 50.3% |
| Operating Margin | 22.1% | 24.3% | 22.7% | 23.1% | 23.5% | 23.6% |
| Net Margin (consolidated) | 17.8% | 19.1% | 18.5% | 18.5% | 18.9% | 19.0% |
| Net Margin (attributable to P&G) | 17.7% | 19.0% | 18.4% | 18.4% | 18.8% | 18.9% |
The full workbook adds 20 historical and 8 projected quarters, plus KPI Drivers · Balance Sheet · Cash Flow Statement · Operating Segments · Pro-Forma / Non-GAAP Reconciliation — every subtotal a live formula, every projection traced to a driver.
Key Takeaways
- A clean beat on both lines, with almost none of it from operating leverage. Net sales of $22,386M topped the ~$22,182M consensus by 0.9% and core EPS of $1.99 beat $1.90 by 4.7%, but core earnings attributable to P&G grew only 1.9% and a 1.2% lower share count supplied roughly 40% of the 3% core EPS growth. Core operating margin was exactly flat.
- The cost picture improved by about $500M after tax and the earnings guide did not move a cent. Commodities went from a ~$200M to a ~$100M after-tax headwind and tariffs from ~$800M to ~$400M after tax, cutting the stated full-year drag from $0.39 to $0.19 per share. That $0.20 is worth 2.9% of the fiscal 2025 core EPS base, more than the entire 1.9% growth the guide midpoint asks for, and all of it is being routed into promotion and marketing rather than earnings.
- Organic volume was zero and the share scoreboard went backwards. The +2% organic print was one point of price and one point of mix. Global aggregate value share fell 30 basis points and only 24 of the top 50 category/country combinations held or grew share, a reading only the first two years of P&G's own ten-year disclosure sit below. Health Care and Fabric & Home Care each shed 2% of volume against what the CFO called a heightened competitive environment.
- The market round-tripped the print inside one session. PG opened 2.8% higher at $156.40 and closed at $152.49, up 0.2%, on 1.6x normal volume, while the S&P 500 gained 0.8%. The tape did the same arithmetic we did: pay for the beat at the open, hand it back once the share and volume detail lands.
- Rating: Initiating at Hold. A self-funding, cash-generative franchise at ~21.9x a guided +2% earnings year with a 2.8% yield is fairly priced, not cheap, and the growth engine is being defended rather than advanced. We want the reinvestment to show up as volume before we pay more.
Results vs. Consensus
Q1 FY2026 scorecard
| Metric | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Net sales | $22,386M | ~$22,182M | Beat | +0.9% |
| Core EPS | $1.99 | $1.90 | Beat | +4.7% |
| GAAP diluted EPS | $1.95 | n/a | n/a | +21% YoY |
| Organic sales growth | +2% | n/a | n/a | vs. 0% to +4% FY guide |
| Core gross margin | 51.5% | n/a | n/a | (50) bps YoY |
| Core operating margin | 26.7% | n/a | n/a | Flat YoY |
| Operating cash flow | $5,408M | n/a | n/a | +26% YoY |
| Adjusted free cash flow productivity | 102% | n/a | n/a | vs. 85% to 90% FY guide |
No independent Street consensus exists for the margin or segment lines, so those rows are measured against the prior-year actual rather than an expectation, and are labelled as such.
Year-over-year comparison
| $M except per-share | Q1 FY2026 | Q1 FY2025 | Change |
|---|---|---|---|
| Net sales | 22,386 | 21,737 | +3% |
| Cost of products sold | 10,887 | 10,421 | +4% |
| Gross profit | 11,499 | 11,316 | +2% |
| Gross margin | 51.4% | 52.1% | (70) bps |
| Selling, general and administrative expense | 5,643 | 5,519 | +2% |
| SG&A as % of net sales | 25.2% | 25.4% | (20) bps |
| Operating income | 5,856 | 5,797 | +1% |
| Operating margin | 26.2% | 26.7% | (50) bps |
| Interest expense | (197) | (238) | (17)% |
| Interest income | 108 | 135 | (20)% |
| Other non-operating income/(expense), net | 268 | (554) | n/m |
| Earnings before income taxes | 6,034 | 5,140 | +17% |
| Income taxes | 1,253 | 1,152 | +9% |
| Effective tax rate | 20.8% | 22.4% | (160) bps |
| Net earnings | 4,781 | 3,987 | +20% |
| Net earnings attributable to P&G | 4,750 | 3,959 | +20% |
| GAAP diluted EPS | $1.95 | $1.61 | +21% |
| Core EPS | $1.99 | $1.93 | +3% |
| Diluted weighted average shares (M) | 2,436.8 | 2,466.0 | (1.2)% |
The 21% GAAP EPS growth is an artefact of the base period, not of this quarter. Q1 FY2025 carried $0.8 billion of after-tax incremental restructuring from the substantial liquidation of the Argentine operations, which is what separates that quarter's $1.61 GAAP from its $1.93 core. Strip the restructuring from both periods and the real comparison is $1.99 against $1.93.
Sequential comparison (vs. Q4 FY2025)
| $M except per-share | Q1 FY2026 | Q4 FY2025 | Change |
|---|---|---|---|
| Net sales | 22,386 | 20,889 | +7.2% |
| Gross profit | 11,499 | 10,258 | +12.1% |
| Gross margin | 51.4% | 49.1% | +230 bps |
| SG&A as % of net sales | 25.2% | 28.3% | (310) bps |
| Operating income | 5,856 | 4,355 | +34.5% |
| Operating margin | 26.2% | 20.8% | +540 bps |
| Net earnings attributable to P&G | 4,750 | 3,615 | +31.4% |
| GAAP diluted EPS | $1.95 | $1.48 | +31.8% |
| Core EPS | $1.99 | $1.48 | +34.5% |
Read the sequential table with care. P&G's July-to-September quarter is structurally its largest and its April-to-June quarter its smallest, so every line above flatters. The sequential comparison carries information in only one place: the direction of productivity. Core operating margin rose 150 basis points year on year in Q4 FY2025 on 560 basis points of gross productivity savings; this quarter it was flat on 230 basis points. Part of that Q4 figure came from variable-compensation adjustments that do not repeat, but the step down is large and it is the reason a 7% sequential sales gain converted into a flat year-on-year core margin.
- Revenue. The $204M of upside versus consensus came without help from volume. Organic volume was flat for the total company and negative in the two segments that together are half of sales. One point of the 3% reported growth came from currency, which reverses the pattern of the prior two years. Acquisitions and divestitures were a net zero.
- Margins. Core gross margin fell 50 basis points despite 140 basis points of gross productivity savings in cost of goods and 50 basis points of pricing, because 100 basis points of adverse mix, 70 basis points of product reinvestment and 70 basis points of tariff and commodity cost landed on top. Core operating margin held flat only because core SG&A fell 40 basis points, and it fell on 90 basis points of overhead productivity plus 40 basis points of sales leverage, not on restraint: reinvestment inside SG&A added 70 basis points.
- EPS. Core net earnings attributable to P&G rose 1.9% to $4,850M. The diluted share count fell 1.2%. Those two combine to the +3.1% that rounds to the reported +3%, which means roughly 1.2 points of the 3 came from the buyback and 1.9 points from the business. Below the line, a 160 basis point lower effective tax rate and a $41M reduction in interest expense both helped; the tax rate is guided to rise for the full year, so that particular tailwind is a first-quarter phenomenon.
Assessment: Revenue
Two percent organic with zero volume is the whole quarter in one line. P&G has now delivered 40 consecutive quarters of organic sales growth, a streak management opened the call with, but the composition has changed in a way the streak conceals. In Q1 FY2025 the same +2% organic print carried a volume component. This one does not. Price contributed a point and mix contributed a point. In North America, the round announced on June 15 took effect only on September 15, so it carried about two weeks of the quarter and will annualise into the next three.
The geography is genuinely two-sided and worth separating. Greater China grew 5% organic with six of seven categories growing, the second consecutive quarter of sequential improvement, and Latin America grew 7% with strength across Mexico, Brazil and the distributor markets. Those are real turns on real interventions. Against them, North America managed +1% organic with consumption in P&G's categories decelerating through the quarter, European focus markets were exactly flat, and the Asia Pacific, Middle East and Africa enterprise region declined. Six of seven regions held or grew, which is the number management led with; the two regions that produce the majority of profit are the two that are flat to barely positive.
Assessment: Margins
Flat core operating margin on 230 basis points of gross productivity is a deliberate outcome, not a shortfall, and management is explicit that it is deliberate. The money is being spent. What makes it a watch item rather than a neutral is the sequential trajectory of the productivity itself: 560 basis points in the June quarter, 230 in this one. Productivity is the engine that is supposed to fund the defence of the categories, and it just halved in the quarter when the defence became most necessary.
The mix drag deserves separate attention. One hundred basis points of adverse mix inside cost of goods is a large number for a company whose stated strategy is trading consumers up. It reflects geographic mix, with faster growth in enterprise markets carrying lower margins, and product mix within categories. Management did not quantify the split, and it declined to give a full-year gross-margin direction of any kind.
Assessment: EPS
Core EPS of $1.99 beat by nine cents, and the full-year guide did not move. That arithmetic matters more than the beat. If the Street held its fiscal 2026 number after banking the Q1 upside, it has to find nine cents to remove from the remaining three quarters. Management's own framing supplies the mechanism: the guide midpoint of $6.96 less the $1.99 already delivered leaves $4.97 for the final nine months against $4.90 in the comparable period of fiscal 2025, or 1.4% growth, and the low end of the guide implies an outright 1.2% decline over those three quarters. The company told investors to expect "modest earnings growth over the balance of the year". That is the guide, correctly read.
Segment Performance
Q1 FY2026 reportable segments
| Segment | Net sales ($M) | % of total | Net sales growth | Organic sales | Organic volume | Net earnings ($M) | Net earnings growth |
|---|---|---|---|---|---|---|---|
| Beauty | 4,143 | 18.5% | +6% | +6% | +4% | 879 | +5% |
| Grooming | 1,817 | 8.1% | +5% | +3% | +1% | 463 | +9% |
| Health Care | 3,220 | 14.4% | +2% | +1% | (2)% | 718 | (3)% |
| Fabric & Home Care | 7,793 | 34.8% | +1% | 0% | (2)% | 1,579 | (3)% |
| Baby, Feminine & Family Care | 5,171 | 23.1% | +1% | 0% | 0% | 1,105 | +4% |
| Corporate | 242 | 1.1% | n/m | n/a | n/a | 36 | n/m |
| Total Company | 22,386 | 100.0% | +3% | +2% | 0% | 4,781 | +20% |
The total net earnings growth of 20% is a consolidated figure that includes the Corporate line and reflects the prior-year restructuring charge sitting inside it. None of the five operating segments grew net earnings by more than 9%, and two of them declined.
Q1 FY2026 net sales drivers
| Segment | Volume | Foreign exchange | Price | Mix | Other | Net sales | Organic sales |
|---|---|---|---|---|---|---|---|
| Beauty | +4% | +1% | +2% | (1)% | 0% | +6% | +6% |
| Grooming | +1% | +2% | +4% | (2)% | 0% | +5% | +3% |
| Health Care | (2)% | +1% | +1% | +2% | 0% | +2% | +1% |
| Fabric & Home Care | (2)% | +2% | +1% | 0% | 0% | +1% | 0% |
| Baby, Feminine & Family Care | 0% | +1% | 0% | 0% | 0% | +1% | 0% |
| Total Company | 0% | +1% | +1% | +1% | 0% | +3% | +2% |
Q1 FY2026 value share by category
| Category | Global value share vs. year ago |
|---|---|
| Skin Care | (1.0) pt |
| Hair Care | (1.0) pt |
| Fabric Care | (0.9) pt |
| Grooming | (0.8) pt |
| Family Care | (0.8) pt |
| Oral Care | (0.3) pt |
| Baby Care | Flat |
| Feminine Care | Flat |
| Home Care | +0.4 pt |
| Personal Health Care | +0.5 pt |
| Personal Care | +0.2 pt |
| Global aggregate value share | (30) bps |
Beauty
The quarter's engine, and the only segment where volume did real work. Organic sales rose 6% on four points of volume and two of price, with Personal Care up high single digits on innovation-driven volume and pricing in North America, Hair Care up low singles, and Skin Care up mid singles on premium mix and pricing. Greater China was central to it: premium body wash innovation on Safeguard and Olay drove 9% Personal Care growth in the region, and SK-II grew double digits with the travel-retail business turning positive.
"Olay premium body wash launched in July, contains Olay facial skin essence and the first ever sparkling liquid to provide visible skin benefits and an unforgettable showering experience. Since launch, the new premium line has grown over 30% in off-line channels and 80% online, driving category growth and Olay share growth." — Andre Schulten, Chief Financial Officer
Net earnings grew 5%, below the 6% sales growth, because sales growth and productivity were partially offset by tariff costs, adverse category mix and higher commodities. The share picture is the discordant note: global Skin Care value share fell a full point and Hair Care fell a full point, even as the segment led the company on volume.
Assessment: The best evidence in the quarter that the integrated-superiority playbook converts when the innovation is genuinely new, and the best argument for the reinvestment. It is also the clearest demonstration that winning on volume and winning on share are not the same thing at P&G right now.
Grooming
The margin story of the quarter. Organic sales rose 3% on four points of innovation-driven pricing, primarily in North America and Europe, and a point of volume, partially offset by two points of adverse product mix. Net earnings grew 9%, the fastest of any segment, and the segment's net earnings margin of 25.5% is the highest in the portfolio. Currency added two points to reported net sales growth, so the 5% headline overstates the underlying by the same amount.
Global Grooming value share fell 0.8 points. This is a segment where P&G is monetising pricing power in the short run while losing ground on the scoreboard, and management flagged that it is streamlining the grooming device portfolio in enterprise markets as part of the restructuring, which will subtract from reported sales going forward.
Assessment: Excellent near-term earnings quality and a deteriorating competitive position. Grooming is the segment most exposed if the pricing-for-innovation model stops being accepted by the consumer.
Health Care
Organic sales rose 1% on two points of favourable mix and one of pricing, against a two-point volume decline. Oral Care organic sales were unchanged as premium innovation mix offset volume declines; Personal Health Care rose low singles on pricing in Latin America and North America, again against falling volume. Latin America Personal Health Care was the standout at 15% organic growth, led by Vicks innovation with Brazil up nearly 30%.
Net earnings fell 3%, and fell 4% on a constant-currency basis, as sales growth and productivity were more than offset by adverse geographic mix and tariff costs. Management identified Oral Care as one of the US categories where promotional intensity stepped up.
Assessment: Mix is carrying this segment and volume is leaking underneath it. A 2% volume decline paired with a 3% earnings decline in a category set that should be defensive is the clearest single reading of the promotional pressure in the quarter.
Fabric & Home Care
The largest segment at 34.8% of sales, and it grew zero organic on a two-point volume decline offset by a point of price. Fabric Care organic sales fell low single digits, driven by volume declines mainly in Europe; Home Care rose low singles on pricing in North America and Europe against volume declines, primarily in Europe. Net earnings fell 3% as productivity was more than offset by adverse product mix, tariff costs and higher commodities. Global Fabric Care value share fell 0.9 points, partially offset by Home Care gaining 0.4.
The European detail management volunteered is the most specific competitive disclosure on the call. Asked about share, the CFO gave a worked example rather than a generality.
"So if you look at Fabric Care, for example, in our Germany business, we were up last year same quarter, 33%. We are down this year because we have competitive activity in the market." — Andre Schulten, Chief Financial Officer
The response is the Tide liquid relaunch, described as the brand's biggest upgrade to liquid detergent in 20 years, which began shipping in the quarter, plus the staged national expansion of Tide evo with an online launch of Tide evo Free & Gentle.
Assessment: A third of the company is not growing, is losing share in its largest category, and is answering a promotional attack with a product relaunch whose payback management concedes is slower. This is where the fiscal 2026 thesis is decided.
Baby, Feminine & Family Care
Flat organic with flat volume, flat pricing and flat mix, which is an unusually inert quarter even by staples standards. Baby Care organic sales rose low singles on premium mix and a unit volume increase; Feminine Care was unchanged; Family Care fell low singles, which management attributed to merchandising investments. Global Baby Care and Feminine Care value share were flat and Family Care fell 0.8 points. Net earnings nonetheless grew 4%, helped by productivity and lower commodity costs.
Management laid out a specific playbook for Baby Care: hold the premium tier with Swaddlers and Cruisers 360, defend the value tier with the Luvs Platinum innovation launched a year earlier, and restage the mid-tier with Pampers Baby Dry in two waves, the first this autumn and the second in spring.
"We have intervened on the value tier with Luvs Platinum innovation which we've launched in the fall of last year, and we have been able to grow share even competing in what is probably the most pressured tier within the Baby Care portfolio." — Andre Schulten, Chief Financial Officer
Assessment: The earnings line is doing better than the top line deserves, which is a productivity outcome and not a demand outcome. The mid-tier Baby Dry restage is the single most testable commitment on the call, with a first read due in the December quarter.
Regional detail
| Region | Q1 FY2026 organic sales | Note |
|---|---|---|
| Focus markets (aggregate) | More than +1% | Developed-market core |
| North America | +1% | Consumption decelerated through the quarter; price/mix added a point |
| European focus markets | 0% | France and Spain strong; Germany and Italy softer |
| Greater China | +5% | Six of seven categories grew; Pampers and SK-II each double digits |
| Enterprise markets (aggregate) | More than +1% | n/a |
| Latin America | +7% | Broad strength across Mexico, Brazil and smaller markets |
| European enterprise | 0% | n/a |
| Asia Pacific, Middle East, Africa enterprise | Down low single digits | Geopolitical and competitive pressure |
Key Topics & Management Commentary
Overall Management Tone: Controlled and unusually specific, with a posture of patient defence rather than confidence in acceleration. Management volunteered granular competitive detail (a named country, a named category, a share sequence to one decimal) instead of retreating behind the aggregate, which reads as candour rather than evasion. The one place the answer stayed framework-level was the question that mattered most: where the roughly $0.20 per share of cost relief is going, which drew a discussion of optionality and volatility rather than a line item.
1. The $500 million that never reached the guide
In July, P&G sized the fiscal 2026 cost stack at roughly $200M after tax of commodity headwind, roughly $1.0 billion before tax (about $800M after tax) of tariff cost, a $250M after-tax net headwind from interest and the tax rate, and a $300M after-tax currency tailwind, netting to $0.39 per share, described in that release as a six percent drag on core EPS growth. Three months later the commodity number is roughly $100M after tax and the tariff number is roughly $500M before tax (about $400M after tax). The combined stack is now $0.19 per share. The other two components are unchanged.
That is roughly $500M after tax, about $0.20 per diluted share, of relief arriving in the first quarter of the year. It is worth 2.9% of the $6.83 fiscal 2025 core EPS base. The guide midpoint asks for 1.9% growth. The relief is larger than the growth. The guide did not move.
Two causes were given. Oil and the petrochemical complex fell, easing the energy side. On tariffs, the larger effect was exclusions for natural materials that cannot be grown domestically, alongside the rescission of Canadian retaliatory tariffs.
"The commodity headwinds, you see the news on the petro complex oil is not -- is coming down. That's helping us from the energy side. And the tariff environment continues to be volatile, but the biggest help on tariffs has been exclusion of materials, natural materials and ingredients that cannot be grown in the U.S." — Andre Schulten, Chief Financial Officer
Assessment: Two defensible reasons were given for not passing the relief through: it is early in a volatile tariff year, and some of the tariff relief was linked to pricing that came out alongside it, so the net P&L effect within the year is smaller than the gross. Both are real. Neither explains the whole $0.20, and management did not claim they did. The honest reading is that the company chose to convert a cost windfall into promotional and marketing firepower for a competitive fight it is currently not winning. That is a defensible allocation of capital and a poor one for the fiscal 2026 earnings line, and investors should price the guide, not the windfall.
2. Organic volume at zero, and what the +2% is made of
Total company organic volume was flat. Pricing added a point and mix added a point. Within that, Beauty contributed four points of volume and Grooming one, while Health Care and Fabric & Home Care each gave back two. Baby, Feminine & Family Care was flat on every driver.
Management opened the call by noting 40 consecutive quarters of organic sales growth and a track toward a tenth consecutive fiscal year of core EPS growth. Both are true and both are streaks measured on metrics that price and buybacks can sustain without a unit moving.
"This marks 40 consecutive quarters of organic sales growth and keeps us on track for the tenth consecutive fiscal year of core EPS growth. Organic sales rounded up to 2%. Volume was in line with prior year." — Andre Schulten, Chief Financial Officer
The word "rounded" is doing work in that sentence, and management chose to use it.
Assessment: For a company whose stated ambition is to expand categories by driving more users and more usage, a flat unit line is the most direct evidence that the ambition is not yet being realised. The North American price increase landed on September 15, so it carried only about two weeks of the quarter; that same pricing will carry full quarters from here, which mechanically supports the next three prints and further delays the point at which volume has to do the work.
3. The share scoreboard: 24 of 50, and a 30 basis point aggregate decline
Global aggregate value share fell 30 basis points and 24 of the top 50 category/country combinations held or grew share, on data through August 2025. P&G discloses that top-50 count as a ten-year annual series on its own slide; only the first two readings in that series sit below 24, and the fiscal 2025 reading was 29. The peak in the disclosed series is 38.
The counterpoint management offered is sequential rather than year-on-year, and it is a fair one. US absolute value share has been rising on a rolling basis while the year-on-year comparison is still lapping a strong base, and the CFO gave the sequence to one decimal.
Q: "Just wanted to touch on the market share stats, the global market share down 30 basis points. I know that can be very impacted by geographic mix to some elements, but even just at the 24 of 50 category country combinations are holding or gaining share is on the low side."
— Lauren Lieberman, Barclays
A: "And the positive read of the U.S. shares would be that if you look sequentially, we are actually increasing absolute share. So past 12, past 6, past 3, past 1 month, our absolute share in the U.S. went from $33.6 to $33.9 to $34.1 to $34.9. So absolute shares are moving in the right direction."
— Andre Schulten, Chief Financial Officer
Management also reported that the most recent one-month global reading was near flat at minus 0.1%, characterising the gap between that and the three- and six-month readings as normal variability.
Assessment: Both readings are true and they point in opposite directions over different windows. The sequential US improvement of more than a point is genuine and is the single best piece of evidence for the bull case. The top-50 count is the metric P&G itself has chosen to report annually for a decade, and it is at the bottom of its own disclosed range. Management committed to exiting the fiscal year with neutral-to-positive US share; that is the checkpoint.
4. North America: decelerating consumption and a promotional attack on the two largest categories
North American organic sales rose 1%, with unit volumes essentially flat for both the market and P&G brands and price/mix adding the point. Consumption in P&G's categories decelerated through the quarter. Management quantified both the level and the expected path, which is more than the usual: the year opened at a value-consumption rate of roughly 2.4% and exited the quarter nearer 1.8% to 1.9%.
"We're now a weaker 2. So 1.8%, 1.9%. Some of that is just variability of base periods. But I do believe that for the next 2 quarters, the consumption will be around the 1.5% to 2% range." — Andre Schulten, Chief Financial Officer
The competitive characterisation was equally direct, and applied specifically to Fabric Care and Baby Care, the two largest US category exposures.
"And as you will have seen in the results, both are not delivering at the level that we want them to deliver. And as you pointed out, what we see is a heightened competitive environment, which is not unexpected, where consumers are a bit more careful in terms of purchase decisions and consumption. The market gets tighter." — Andre Schulten, Chief Financial Officer
Intense promotion was also flagged in Oral Care and in Baby Care's mid-tier, where management described the promotional activity as "very aggressive rollbacks".
Assessment: A category growth rate of 1.5% to 2% is below the 2% global market growth assumption sitting at the centre of the full-year guide, and well below the 3% to 4% management says the strategy is designed to restore. North America is the region where the guide has the least cushion, and it is guided to get slower before it gets faster.
5. The September pricing round, and what it was actually for
P&G announced US pricing on June 15 and it took effect on September 15. Management sized it and, more usefully, attributed it.
"On the pricing question, yes, we've taken in the U.S., we've announced pricing in July. It's gone into effect in September. Most of the pricing was innovation-driven and in aggregate, it's about a 2%, 2.5% price increase across the entire portfolio." — Andre Schulten, Chief Financial Officer
Pressed on whether the halved tariff number changes the pricing plan, management said no: the underlying tariffs that drove the need for pricing had not really changed, the biggest movement was on retaliatory tariffs abroad, and the price effects linked to those (Canada specifically) were withdrawn alongside them.
Management also noted that the pricing transition caused trade-inventory volatility within the quarter, although shipments were largely in line with offtake for the quarter as a whole.
Assessment: This is the cleanest answer on the call, and it is a favourable one: pricing framed as innovation-funded rather than cost-recovery is the version that survives a consumer downturn. It also explains why the halved tariff estimate does not release pricing, and why the corresponding relief had to go somewhere other than the guide.
6. Greater China: the one unambiguous turn
China grew 5% organic with six of seven categories growing, following a prior quarter of improvement. Management was careful to describe it as two points on a line rather than a trend, and to attribute it to specific interventions made roughly two years earlier: a rebuilt distributor network with a changed incentive system, locally grounded innovation, and a changed approach to communication and to strategic online customers.
"But now we have 2 points on -- that we can connect and both points are pointing in the right direction. But again, I would urge us to be also cognizant of the fact that we're dealing with a volatile market environment." — Andre Schulten, Chief Financial Officer
Pressed specifically on whether the distribution rework produced a one-time benefit, management said it did not, describing it as a structural change that should compound.
On the call the CFO cited China Mainland up 6%, SK-II up 12% and Baby Care up 20%, against the prepared remarks' Greater China organic figure of 5% and the description of Pampers and SK-II each growing double digits. The figures reference different perimeters and the prepared-remarks number is the one used above.
Assessment: The most credible operational story in the quarter, and the one with the clearest causal chain from intervention to result. It is also the region management is least willing to extrapolate from, and the market there is still contracting. Worth watching, not yet worth underwriting.
7. Latin America and the enterprise-market split
Latin America grew 7% organic, with Brazil up around 6% to 7% and Mexico up 4%. Personal Health Care in the region grew 15%, led by Vicks innovation, with Brazil up nearly 30%. Against that, the European enterprise region was flat and the Asia Pacific, Middle East and Africa enterprise region declined low single digits, which management attributed to geopolitical, consumer and competitive pressure and expects to persist.
Management's forward framing put enterprise markets at roughly 3% to 4% market growth and developed markets at roughly 2%, with China described as the wild card and still negative on market growth.
Assessment: Latin America is doing genuine work and is the reason total enterprise-market growth cleared 1% despite two of three enterprise regions being flat or down. It also carries lower margins, which is part of the adverse geographic mix showing up in Health Care and Beauty earnings. Growth mix is currently a margin headwind.
8. Productivity stepped down, and the restructuring that is meant to replace it
Gross productivity savings inside core operating margin were 230 basis points, against 560 basis points in the June quarter. Within cost of goods, productivity delivered 140 basis points; within SG&A, 90 basis points. Management restated the ambition behind it: up to $1.5 billion before tax of gross savings in cost of goods, enabled by platform programmes under the Supply Chain 3.0 banner, plus marketing-productivity and overhead reductions.
The headcount element is the largest single commitment the company has outstanding: a reduction of up to 7,000 non-manufacturing roles, up to 15% of the non-manufacturing workforce, across fiscal 2026 and fiscal 2027. Management said execution was on plan.
"We are right now perfectly on track on all elements of the restructuring execution. This is never easy, especially when we're talking about reducing our enrollment. I think the organization is taking it in stride because the mission is clear." — Andre Schulten, Chief Financial Officer
Assessment: The restructuring is the mechanism by which the entire thesis is supposed to work: cut structural cost, fund innovation and demand creation, restore category growth, recover share. The mechanism is intact and on schedule. What the quarter shows is that the output of the mechanism has stepped down sharply at the exact moment the demands on it have increased. No dollar figure for fiscal 2026 productivity delivered was given.
9. Tide's biggest liquid upgrade in 20 years, and Tide evo's careful first step
The Fabric Care response has two parts. The core relaunch is Tide's boosted formula, described as the brand's biggest upgrade to liquid detergent in 20 years, which started shipping in the quarter. The adjacency is Tide evo, built on a functional-fibres platform with no plastic bottle and no water, which entered the first stage of national expansion with an online launch of Tide evo Free & Gentle. Management said test-market sales had been highly incremental to category growth and that retailer demand had run well above initial expectations, and that capacity is being added for an eventual national launch.
Management was also explicit about the trade-off the approach involves against a promotional attack.
"Last comment, this plan takes longer. It's not as easy as throwing promotion funding out there. But again, we believe that is the way to both create value for our consumers and for our retail partners and shareholders." — Andre Schulten, Chief Financial Officer
Assessment: The strategic logic is sound and the honesty about the timeline is welcome. The practical consequence is that the largest segment in the portfolio is running a slower playbook than its competitors for at least the next several quarters, while share is already declining. No sizing was given for evo at any level: no distribution figure, no revenue figure, no share figure.
10. Portfolio action stays "on the fringes"
The restructuring's portfolio component produced a list of specific but small actions: an import model with local distributors in Pakistan, discontinuation of laundry detergent bars in India and the Philippines, exits from low-tier oral care in some enterprise markets, focusing Olay on the most productive European markets, and streamlining grooming devices in focus and enterprise markets. Asked whether larger action, either divestiture or acquisition, was coming, management described the portfolio work as "really on the fringes" and closed the door firmly.
Q: "If you -- can you expand on that a little bit in terms of potentially bigger changes to the portfolio to make a step change in terms of the growth trajectory, either more culling -- more substantial culling of the portfolio or potentially looking the opposite way in terms of filling some of the gaps with inorganic growth."
— Olivia Tong, Raymond James
A: "And the type of change you've seen us announce in this release, that's about the type of change you should expect. There's nothing more dramatic that we're planning to do. We're very comfortable with the core portfolio that we're in."
— Andre Schulten, Chief Financial Officer
In its place management offered an organic sizing of the opportunity: roughly $5 billion from serving underserved consumers in North America, roughly $10 billion from lifting European household penetration toward best-in-class, and roughly $15 billion from bringing enterprise markets with Mexico-like GDP per capita to Mexico-like consumption. Management acknowledged these were "numbers on the piece of paper until you start allocating resources to those ideas".
Assessment: A $30 billion organic opportunity map is a strategy statement, not a forecast, and management said as much. The useful information is the negative: investors hoping the restructuring would culminate in a meaningful portfolio reshaping have been told, unprompted and unambiguously, that it will not. Any re-rating has to come from the existing portfolio growing faster.
11. Capital return held, capital spending ran hot
P&G returned $3,799M in the quarter, $2,549M in dividends and $1,250M in repurchases, against a full-year plan of roughly $10 billion of dividends and roughly $5 billion of buyback. Operating cash flow of $5,408M rose 26% year on year, and adjusted free cash flow of $4,896M represented 102% of net earnings, well ahead of the 85% to 90% full-year guide.
Capital spending of $1,200M was 5.4% of net sales, above the guided 4% to 5% range, reflecting capacity additions across several categories and the cash cost of the restructuring. Management flagged the same combination as the reason full-year cash conversion is guided below the Q1 run rate.
Assessment: The cash engine is in excellent shape and is the strongest single leg of the investment case. Quarter-one cash conversion at 102% against an 85% to 90% guide is a comfortable start, but the capex line is already above its range and the restructuring cash costs are still ramping, so the gap between Q1 and the full-year guide is a real forecast and not conservatism.
12. Agentic commerce, answered as opportunity
Asked how a supplier gets into a basket when consumers shop through prompts rather than shelves, management gave a channel-evolution answer rather than a capability answer, listing the sequence of retail and media transitions the company has navigated over 187 years and arguing that the fundamentals transfer: understanding the consumer, understanding how an agent extracts product information, and working with retail partners on access to those algorithms.
Assessment: Reasonable framing and no new information. P&G's structural advantage in an agent-mediated channel is unproven in either direction; there is no disclosure here to model. It goes in the watch column, not the thesis.
Guidance & Outlook
Every headline range was maintained. The composition beneath them changed materially.
| Metric | Prior (July 29, 2025) | Current (October 24, 2025) | Change |
|---|---|---|---|
| All-in net sales growth | +1% to +5% | +1% to +5% | Maintained |
| Organic sales growth | 0% to +4% | 0% to +4% | Maintained |
| Core EPS growth | 0% to +4% | 0% to +4% | Maintained |
| Core EPS range | $6.83 to $7.09 (mid $6.96) | $6.83 to $7.09 (mid $6.96) | Maintained |
| All-in diluted EPS growth | +3% to +9% | +3% to +9% | Maintained |
| Currency-neutral core EPS growth | n/a | -2% to +2% | n/a |
| Core effective tax rate | 20% to 21% | 20% to 21% | Maintained |
| Adjusted free cash flow productivity | 85% to 90% | 85% to 90% | Maintained |
| Capital spending (% of net sales) | 4% to 5% | 4% to 5% | Maintained |
| Dividends | ~$10B | ~$10B | Maintained |
| Share repurchases | ~$5B | ~$5B | Maintained |
The fiscal 2026 earnings headwind, itemised
| Item | July 29, 2025 guide | October 24, 2025 guide | Change |
|---|---|---|---|
| Commodity costs | ~$200M after-tax headwind | ~$100M after-tax headwind | Halved |
| Tariffs | ~$1.0B before tax / ~$800M after tax | ~$500M before tax / ~$400M after tax | Halved |
| Net interest expense + core tax rate | ~$250M after-tax headwind | ~$250M after-tax headwind | Unchanged |
| Foreign exchange | ~$300M after-tax tailwind | ~$300M after-tax tailwind | Unchanged |
| Combined impact on core EPS | ($0.39) | ($0.19) | +$0.20 |
| Core EPS guidance range | $6.83 to $7.09 | $6.83 to $7.09 | Unchanged |
Implied quarter-over-quarter ramp: Q1 delivered $1.99 of core EPS. The guide midpoint of $6.96 leaves $4.97 for the remaining nine months against $4.90 in the comparable fiscal 2025 period, or +1.4%. The low end of $6.83 leaves $4.84, a 1.2% decline. The high end of $7.09 leaves $5.10, or +4.1%. Management framed the same shape in words, saying it expects modest earnings growth over the balance of the year as investment in innovation and competitiveness increases, particularly in the US and Europe.
Implied phasing of organic sales: Management named Q2 as the softest growth quarter of the year and the second half as stronger than the first, attributing the Q2 step-down to a prior-year base inflated by two order spikes around the October 2024 port strike and the threatened January 2025 strike. The guide also carries a 30 to 50 basis point drag from brand and product-form discontinuations under the restructuring.
Street at: Consensus for the quarter was $1.90 of core EPS, so the print ran nine cents ahead. With the range unchanged, any Street model that holds its full-year number has to take those nine cents out of the next three quarters. The guide midpoint of $6.96 is the only company-supplied anchor, and it now sits closer to the middle of a year that has already banked its beat.
Guidance style: Conservative by construction and getting more so. P&G reaffirmed a range it set before roughly $500M after tax of cost pressure came out, giving it a cushion it did not have in July. The company retains the option to spend that cushion or to release it; management was explicit that it wants to preserve the ability to invest. Investors should treat the low half of the range as the working case and any release of the cushion as upside that has to be earned by a share inflection first.
Analyst Q&A Highlights
Whether the restructuring is landing internally and what it buys competitively
The call opened on the June restructuring, with the question split between internal reception and external competitiveness. Management walked all three components (portfolio, supply chain, organisation) and characterised the execution as on plan, with organisation designs completed and differentiated by category. The explicit framing of the payoff was near-term cost to fund an innovation programme over the next 12 to 18 months, and a longer-term strengthening of both the portfolio and the organisation.
Q: "So I just wanted to touch on the restructuring you announced back in June, given you're now a few months into putting the initial plans into place. A, just how do you think the organizational changes are being received internally by your workforce, given there's a significant reorg and also rationalization of the job roles at P&G?"
— Dara Mohsenian, Morgan Stanley
A: "The short-term benefit is cost and fuel for us to be able to invest over the next 12 to 18 months into the very strong innovation programs that we're launching. I think the longer-term benefit is just an even strengthened portfolio and a strengthened organization."
— Andre Schulten, Chief Financial Officer
Assessment: The answer confirms that the restructuring's near-term purpose is to pay for a defensive fight, not to expand margins. That reconciles the flat core operating margin with the "perfectly on track" characterisation, and it sets the benchmark: the savings are meant to show up as growth, so growth is where they should be graded.
What the competitive response looks like in US Fabric Care and Baby Care
A direct request for real-time competitive colour in the two largest US categories drew the most candid passage of the call. Management conceded both categories are underperforming its own expectations, named increased promotion as the competitive response it is seeing, and said P&G's answer would be integrated superiority rather than matching promotion, while conceding the approach is slower.
Q: "But maybe you can just give us a bit more detail on what you're seeing real time from a competitive standpoint, both in North America Fabric Care and Baby Care."
— Peter Galbo, Bank of America
A: "Our response to a more competitive environment has to be a more integrated answer, which is what we are executing across both baby and Fabric Care. So when we talk about driving integrated superiority, that's what we mean. And while value or promotion might be a component to that answer, the real solution here to create sustainable growth is to drive innovation and drive superiority, communicate that innovation with the right claims, meaningful to the consumer, meaningful to the retailer, get the retailer support online and in physical stores and thereby create value for the consumer that is attractive."
— Andre Schulten, Chief Financial Officer
Assessment: A strategically coherent answer with a commercially uncomfortable implication. P&G is choosing to lose some share in the near term rather than defend it with price, and it is saying so out loud. That is the right long-run call if the innovation is genuinely superior, and it is the wrong call if the category is repricing structurally.
The 24-of-50 share statistic and where the damage sits
The share scoreboard drew the most pointed challenge of the call, framed around both the aggregate 30 basis point decline and the low top-50 count. Management did not dispute either figure, offered a sequential US improvement as the counterweight, and located the pressure specifically in Baby Care mid-tier rollbacks, Fabric Care promotion and a period of intense Oral Care promotion, with a European overlay from competitors returning to the arena.
Q: "Maybe just where might you call out some particular hotspots of activity things where is it a matter of macro and positioning and relative affordability at this time? Is it a matter of the innovation that's yet to come, you think will be the answer, but it was a pretty stark statistic, and I'd love to get your thoughts on that."
— Lauren Lieberman, Barclays
A: "We've seen very aggressive rollbacks and promotion activity in the Baby Care mid-tier section. We also see very intense promotions in Fabric Care. We've seen a period of intense promotion in Oral Care. So certainly, the competitive aggressiveness has increased. And the way we respond is more structural. It takes a bit more time."
— Andre Schulten, Chief Financial Officer
Assessment: The characterisation of the question as stark was accepted rather than deflected, which is to management's credit. What did not come was any disaggregation of the 24: no split between held and grew, and no indication of how many of the 26 are deteriorating rather than merely lapping a strong base.
Where the halved cost headwind actually went
The single most important exchange of the call. The question did the arithmetic in public, put the number at roughly $0.20 per share of released headwind against an unchanged EPS guide, and asked directly where it was going. The answer named early-year timing, continued tariff volatility, and the fact that some tariff relief was linked to pricing that came out with it, before arriving at the real reason: management wants to preserve the ability to invest.
Q: "And then if you sum up all the items that you call out, it's now like a $0.19 headwind before it was $0.39. So you have some flexibility about $0.20, but obviously, the EPS guidance is unchanged. So can you walk us through like what is the offsetting factor?"
— Filippo Falorni, Citi
A: "So volatility, it's still early, and you're very right, we want to absolutely preserve our ability to continue to invest because we have proof and we continue to be convinced based on the consumer reaction to where we successfully invested in integrated priority that this is the right path forward."
— Andre Schulten, Chief Financial Officer
Assessment: The answer is honest and it is not quantified. No allocation of the $0.20 was offered by line, by category or by region, and the "proof" invoked was the consumer response in the places where investment has already worked, not a forecast of what the incremental spend returns. Investors are being asked to fund an unspecified defence on the strength of a directional argument.
How much of a step down the December quarter represents
A follow-up on North America pushed for a frame on the Q2 base effects. Management gave the consumption path, explained that the prior-year comparison is inflated by roughly a point from port-strike order spikes, and then compressed the whole outlook into two sentences that are the most useful forward guidance on the call.
Q: "And then just related on the comment on the port strikes that will make 2Q the soft this quarter. Is there a way to frame how much of an impact these laps will have? Or maybe how much of a step back you would expect from where we started the year."
— Peter Grom, UBS
A: "And if there's 2 things you need to take away is quarter 2 is going to be lower than quarter 1 and half 2 is going to be higher than half 1. That's about the best logic I can give you."
— Andre Schulten, Chief Financial Officer
Assessment: A clear steer that the next print is the low point of the year, which sets up an easier reception for a weak December quarter and puts the entire full-year guide on a second-half reacceleration that is currently asserted rather than evidenced. The base effect is real and quantified at roughly a point, so a sub-2% December organic print is the expected outcome, not the bear case.
Whether affordability has become the driver of consumer choice
A question on whether affordability is now the primary consumer driver, and what levers beyond innovation are available, drew a deliberate reframing. Management rejected "affordability" as the right word, substituted value defined as price over integrated performance, and supported it with the observation that private label is losing ground.
Q: "And I guess my question is, as you look at the other side of that, which is the consumer side and the research you're doing on the consumer, has affordability become a bigger driver of consumer choice in the quarter?"
— Robert Ottenstein, Evercore
A: "We also see continued decline of private label. Actually, private label shares in the U.S. are now down 50 basis points. So for the first time, private label shares dropping below 16%."
— Andre Schulten, Chief Financial Officer
Assessment: The private-label data point is the strongest counter to the trade-down narrative available in the quarter, and it argues that P&G's share losses are to branded competitors running promotions rather than to a consumer abandoning brands. That is a materially better problem to have, because it is cyclical rather than structural. It also means the losses are to competitors who can be out-innovated, which is precisely the bet management is making.
Whether the China recovery contains a one-time distribution benefit
A clarifying question tested whether the flip to a new distributor structure had produced a near-term stocking benefit rather than genuine consumption improvement. Management rejected the premise directly and described the mechanism as a structural change with a compounding profile.
Q: "And then on China, a lot of conversations around distribution and distribution changes. Was there anything onetime in there as it relates to sort of a near-term benefit from flipping into a new distribution structure? Or is what we're seeing more related to an improvement in consumption."
— Kaumil Gajrawala, Jefferies
A: "I know there were not any onetime distribution gains that drive these results. It is just a streamlining and changing the incentive system for the distributor network. So we have fewer distributors. They are better aligned to what we're trying to do in terms of quality execution in stores and online, and that is starting to pay dividends."
— Andre Schulten, Chief Financial Officer
Assessment: A clean denial on a question that had a clean answer available, which is the right test to have applied. The claim is falsifiable within two quarters: a structural go-to-market improvement should hold; a stocking effect should reverse. Management also said it expects the benefit to accelerate slowly over time, which sets a higher bar than mere persistence.
Whether the pricing plan changes now that the tariff number has halved
The final question tested the link between the tariff estimate and the pricing architecture, noting that a previously discussed mid-single-digit increase on roughly a quarter of US SKUs had been framed as tariff mitigation. Management decoupled the two, saying the underlying tariff exposure driving the need for pricing had not changed and that the movement was on retaliatory tariffs abroad, where the associated pricing had been withdrawn alongside them.
Q: "So I think previously, there was a discussion of taking a mid-single-digit pricing on about 25% of your U.S. SKUs to mitigate the tariff impact. So now that the tariff impact is half of what it was before curious on how that affects your pricing strategy, if at all?"
— Victor Ma (for Robert Moskow), TD Cowen
A: "The underlying tariffs that have contributed to the need for pricing has not really changed. The biggest change in the tariff exposure has been retaliatory tariffs on the other side. And those pricing effects have been taking out, I was talking about Canada. But in the U.S., the majority of the pricing was underlying innovation-based with tariffs being a contributor, but not the main contributor, so no change to pricing approach."
— Andre Schulten, Chief Financial Officer
Assessment: Consistent with the guidance answer and with the pricing characterisation earlier in the call, which is worth noting because a company under cost pressure has an incentive to describe cost-recovery pricing as innovation pricing. The two answers hold together, and the claim carries a testable consequence: an innovation-funded price increase should not need to be promoted away.
What They're NOT Saying
- The chief executive transition, ten weeks out: P&G announced on July 28, 2025 that Shailesh Jejurikar would succeed Jon Moeller as President and Chief Executive Officer effective January 1, 2026, with Mr. Moeller becoming Executive Chairman. The handover is ten weeks after this call. It was not mentioned once, no analyst asked, and the incoming CEO was not on the line. Whether the fiscal 2027 investment posture survives the change is an open question that nobody put to management.
- Any gross-margin or operating-margin direction for the year: Guidance covers sales, EPS, tax rate, cash conversion, capex and shareholder return. It does not include a margin target of any kind, and none was offered when the quarter's core gross margin fell 50 basis points.
- The composition of "24 of 50": The metric combines share held with share grown, and P&G reports only the combined count. How many of the 24 merely held, and how many of the 26 are structurally weakening rather than lapping a strong base, is the information that would make the statistic actionable. It was not given and was not requested.
- Any number at all for Tide evo: Described as highly incremental in test market with retailer demand above expectations, entering national expansion, with capacity being added. No distribution figure, no revenue figure, no share figure, no timeline for the full national launch.
- Where the $0.20 per share is being spent: The reduced cost stack is quantified to the $100 million. The offsetting reinvestment is described only as preserving the ability to invest. No split by region, category or spend type was offered, which makes the trade impossible for an outside model to verify.
- A fiscal 2026 productivity dollar figure: The ambition is stated as up to $1.5 billion before tax in cost of goods over the programme. What fiscal 2026 alone is expected to deliver was not given, despite productivity being the single mechanism that funds the entire strategy and despite the quarterly rate having halved sequentially.
- The size of Family Care's "merchandising investments": Family Care organic sales fell low single digits and global Family Care share fell 0.8 points, both attributed to merchandising investments. No dollar value, no duration, no indication of whether the investment is being recovered.
- Any update on the Glad joint-venture exit: The July guidance embedded an expected gain from exiting the Glad joint venture with Clorox of $0.10 to $0.13 per share inside the GAAP EPS range. The October release restates the GAAP range without restating that component, and neither the release nor the call revisited its timing.
- Where the adverse mix is coming from: One hundred basis points of unfavourable mix hit core gross margin, the largest single negative in the bridge. Management attributed mix pressure variously to geography and product within individual segment commentary, but offered no split of the consolidated number.
Market Reaction
- Pre-print setup: PG closed at $152.21 on October 23, down 9.2% year to date against a 14.6% gain for the S&P 500, down 10.3% over the trailing twelve months and effectively unchanged over the trailing thirty days. The 52-week closing range entering the print was $147.42 to $179.70, putting the stock roughly 3% above its own 52-week low and 15% below its high.
- Opening reaction: The stock opened at $156.40, a 2.8% gap, consistent with pre-market quotes reported in the 2.1% to 2.5% range, and reached $157.40 intraday, up 3.4%.
- Session close: $152.49, up 0.2% or 28 cents. The intraday low of $151.53 was below the prior close, so the stock traded on both sides of unchanged after the gap.
- Volume: 12.0 million shares against a 7.4 million 30-day average, 1.6 times normal.
- Relative: The S&P 500 gained 0.8% on the session, so PG lagged the index by roughly 60 basis points on a day it opened nearly 3% higher.
The shape of the day is the most useful piece of information in it. A 2.8% gap on a 0.9% revenue beat and a 4.7% EPS beat is a proportionate opening reaction for a defensive name that had de-rated 10% over a year. Giving all of it back by the close, on 1.6 times volume and against a rising tape, is not a proportionate follow-through. Something in the detail changed minds during the session.
The candidates are not mysterious. The beat is thin once decomposed: nine cents of core EPS upside, of which the share count supplied a meaningful part, on a quarter with zero volume. The share disclosure, which arrives on the slides rather than in the release headline, shows a 30 basis point aggregate decline and a top-50 count at the bottom of its own ten-year range. And the guidance, held flat through roughly $500 million after tax of cost relief, tells anyone who does the arithmetic that the remaining nine months are guided to 1.4% core EPS growth at the midpoint. Each of those is visible only on inspection, which is exactly the profile of a print that opens on the headline and closes on the footnotes.
The positioning context matters too. PG entered this print as an underperformer in a market up nearly 15% year to date, which is a setup that normally rewards any good news. That the stock could not hold a 3% gap in that setup is a sign the marginal buyer is waiting for volume, not for a beat.
Street Perspective
Debate: Is holding the guide through a $500 million cost improvement conservatism or a warning?
Bull view: The bull case on the Street reads the unchanged range as classic P&G under-promising. The company has banked a cushion it did not have in July, the year is only a quarter old, the tariff environment can move again in either direction, and management has explicitly reserved the right to spend or release the money. On this reading the low end of the range is now close to unreachable and the practical guide is the upper half.
Bear view: The bear camp reads the same facts as an admission that the competitive spend required to defend the portfolio has risen by roughly the amount the costs fell. Under that reading the relief is not a cushion at all: it is already committed, and if promotional intensity increases further there is nothing left to absorb it. The tell, bears argue, is that management declined to guide margin in any form.
Our take: The bears have the better of it on the facts, the bulls on the timing. Management said plainly that it wants to preserve the ability to invest, which describes money already committed rather than money held in reserve. But the year is young, the tariff estimate has already moved once, and a company that reaffirms a range it set under worse assumptions retains genuine optionality. Our working case is the low half of the range, with the upper half available only if the share metric inflects and the spend can be throttled back.
Debate: Does integrated superiority beat promotion, or just cost more?
Bull view: The optimistic case points to the evidence within the quarter itself. Beauty grew volume 4% on genuine innovation. Latin American Personal Health Care grew 15% on Vicks innovation. Chinese Baby Care and SK-II grew double digits on locally grounded product work. Private label is losing share in the US, which says the consumer still pays for performance. Where P&G has actually executed the playbook, it works, and management calls this year's innovation programme very strong.
Bear view: Skeptics note that the same quarter produced a full point of global share loss in Skin Care and in Hair Care, both inside the segment held up as the proof case, and 0.9 points in Fabric Care. If the playbook were beating promotion, it would be beating it somewhere on the scoreboard. Management conceded that the approach takes longer, which in a promotional war means ceding share for several quarters while a competitor compounds distribution and habit.
Our take: Both are describing the same mechanism at different stages. Innovation-led defence does work, and it does lag. The question that decides it is not philosophical but empirical: does the top-50 count recover toward the high twenties by the fiscal-year exit, as management committed it would for US share? If it does, the bulls are right and this quarter was the trough. If 24 becomes the run rate, the strategy is being outspent and the multiple has further to fall.
Debate: Is ~21.9x for a 2% grower a defensive premium or a de-rating still in progress?
Bull view: The constructive view holds that P&G at 21.9 times the fiscal 2026 guide midpoint is already cheap relative to its own history, with the stock down 10% over twelve months while the index rose, a 2.8% dividend yield, a fortress balance sheet, 102% first-quarter cash conversion and roughly $15 billion of annual shareholder return. In a market this concentrated, a de-rated defensive with a self-funding cost programme is a reasonable place to be paid to wait.
Bear view: The bear framing is simple arithmetic. Twenty-two times is a growth multiple, and the company is guiding to 0% to 4% core EPS growth with the midpoint at 2% and the remaining nine months at 1.4%. A 2.8% yield plus 2% earnings growth is a mid-single-digit total return before any multiple change, which loses to the index over most periods. If the multiple compresses toward 19 times on a second soft year, the yield does not cover it.
Our take: The bear arithmetic is correct and the bull case depends on a re-rating that has to be earned. Our fair value range of $146 to $160 brackets the current price, which is the honest conclusion: there is no valuation edge here in either direction today. The de-rating from the mid-twenties has already happened; whether it stops at 22 times depends entirely on whether fiscal 2027 can be framed as an acceleration year at the January and April calls.
Model Update Needed
| Item | Guide or Q1 run-rate | Our FY2026 assumption | Reason |
|---|---|---|---|
| Organic sales growth | 0% to +4% (mid +2%) | ~+2.0% | Q1 at +2% with zero volume; Q2 guided softest on a port-strike base; H2 improvement is comp-aided |
| Core EPS | $6.83 to $7.09 (mid $6.96) | ~$6.90 | Implied 9M growth of +1.4% at the midpoint looks full against rising reinvestment and a higher full-year tax rate |
| Core gross margin | (50) bps in Q1 | (30) to (50) bps | 70 bps of tariff and commodity still in the run rate; 100 bps of adverse mix; reinvestment stepping up |
| Core operating margin | Flat in Q1 | Flat to +25 bps | Productivity fell to 230 bps from 560 bps sequentially; the released cost headwind is earmarked for spend |
| Capital spending (% of sales) | 4% to 5% guided; 5.4% in Q1 | 4.5% to 5.0% | Capacity additions across several categories plus restructuring cash costs |
| Adjusted FCF productivity | 85% to 90% guided; 102% in Q1 | ~88% | Q1 flattered by working capital and the 2017 Tax Act add-back; capex and restructuring cash build through the year |
| Shareholder return | ~$15B (~$10B dividend, ~$5B buyback) | ~$15B | Unchanged; Q1 delivered $3.8B and the balance sheet supports the plan |
Valuation impact: On a fiscal 2026 core EPS assumption of roughly $6.90 to $6.96, a 21.0x to 23.0x range produces a fair value of approximately $146 to $160. The stock closed the reaction session at $152.49, which sits in the middle of that band at 21.9 times the guide midpoint. Adding the 2.8% dividend yield, our framework implies a low-to-mid single digit twelve-month total return, in line with rather than ahead of the market. The upside case requires the share metric to inflect and a fiscal 2027 framed as an acceleration; the downside case is a second consecutive low-single-digit earnings year and a multiple that resets toward 19 times, or roughly $131.
Thesis Scorecard Post-Earnings
This is our first published work on P&G, so the pillars below are established rather than graded. Each carries the status tag we will track against future quarters.
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1: Second-half FY26 organic reaccelerates toward the middle of the 2% to 4% algorithm | Neutral / Unproven | Management guided Q2 below Q1 and H2 above H1, and the improvement is substantially base-effect driven. North American consumption is guided to 1.5% to 2%, below the 2% global assumption at the centre of the guide. Asserted, not evidenced. Status: AT RISK. |
| Bull #2: Productivity and restructuring self-fund reinvestment and protect EPS | Confirmed | 230 bps of gross productivity held core operating margin flat through a 50 bps core gross margin decline. Restructuring described as on plan across all three components; up to 7,000 non-manufacturing roles over FY26 and FY27; up to $1.5B before-tax COGS savings ambition. The sequential step down from 560 bps is the watch item. Status: ON TRACK. |
| Bull #3: Capital-return durability and defensive quality | Confirmed | $3.8B returned in the quarter, 102% adjusted FCF productivity, operating cash flow up 26%, ~$15B FY26 plan intact. Status: ON TRACK. |
| Bear #1: Organic growth has stalled on weak volume and US share loss | Confirmed | Zero organic volume; global aggregate value share down 30 bps; 24 of top 50 combinations held or grew, at the bottom of P&G's own ten-year disclosure; share down in six of eleven reported categories including a full point each in Skin Care and Hair Care. Status: EMERGING. |
| Bear #2: Margin and cost pressure from tariffs, mix and reinvestment | Partly challenged | The external cost picture improved materially: commodity and tariff headwinds each halved, cutting the stated FY26 drag from $0.39 to $0.19 per share. But 70 bps of tariff and commodity remained in the quarter's gross margin bridge alongside 100 bps of adverse mix, and the relief was routed to reinvestment rather than earnings. Status: CONTAINED. |
Overall: The defensive and self-funding legs of this business are in good order and are confirmed by the quarter. The growth leg is not working: volume is at zero, share is declining on the company's own preferred metric, and the cost relief that arrived is being spent defending the position rather than expanding it. The thesis starts balanced, with the burden of proof on the second-half reacceleration.
Action: Hold. We would upgrade on evidence that the top-50 share count is recovering with a volume component behind it, or on a de-rating toward the high $130s that pays us to wait. We would downgrade if December-quarter organic sales come in below 1%, if the top-50 count falls further, or if the fiscal 2027 framing at the January or April call implies a third consecutive low-single-digit earnings year.